Cardiac troponin I, cardiac troponin-specific autoantibodies and natriuretic peptides in children with hypoplastic left heart syndrome

Interactive Cardiovascular and Thoracic Surgery

Volumn 18, Issue 1, 2014, Pages 80-85

  Eerola, Anneli ^a   Poutanen, Tuija ^a   Savukoski, Tanja ^b   Pettersson, Kim ^b   Sairanen, Heikki ^c   Jokinen, Eero ^c   Pihkala, Jaana ^c  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Autoantibodies; Congenital; Hypoplastic left; Natriuretic peptides; Troponin

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AUTOANTIBODY; CARDIAC TROPONIN AUTOANTIBODY; HEMOGLOBIN; N TERMINAL PROATRIOPEPTIDE; NATRIURETIC FACTOR; TROPONIN I; UNCLASSIFIED DRUG; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; N-TERMINAL PROATRIAL NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); PROTEIN PRECURSOR;

ANTIBODY BLOOD LEVEL; ARTICLE; CAVOPULMONARY CONNECTION; CHILD; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; GLENN SHUNT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOPLASTIC LEFT HEART SYNDROME; INFANT; MALE; NORWOOD PROCEDURE; OXYGEN SATURATION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; TRICUSPID VALVE REGURGITATION; BLOOD; CASE CONTROL STUDY; FONTAN PROCEDURE; IMMUNOLOGY; NEWBORN; PATHOPHYSIOLOGY; TIME; TREATMENT OUTCOME;

ATRIAL NATRIURETIC FACTOR; AUTOANTIBODIES; BIOMARKERS; CASE-CONTROL STUDIES; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FONTAN PROCEDURE; HUMANS; HYPOPLASTIC LEFT HEART SYNDROME; INFANT; INFANT, NEWBORN; MALE; NATRIURETIC PEPTIDE, BRAIN; NORWOOD PROCEDURES; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; TIME FACTORS; TREATMENT OUTCOME; TROPONIN I;

EID: 84891365734     PISSN: 15699293     EISSN: 15699285     Source Type: Journal    
DOI: 10.1093/icvts/ivt430     Document Type: Article

References (22)

1. Gewillig M. Ventricular dysfunction of the functionally univentricular heart: management and outcomes. Cardiol Young 2005;15:31-4.
2. Almeida CM, Carrapato MR, Pinto F, Pinto M, Ferreira S, Schmitt D et al. Biochemical markers of neonatal myocardial dysfunction. J Matern Fetal Neonatal Med 2011;24:568-73.
3. Baum H, Hinze A, Bartels P, Neumeier D. Reference values for cardiac tro-ponins T and I in healthy neonates. Clin Biochem 2004;37:1079-82.
4. Korff S, Katus HA, Giannitsis E. Differential diagnosis of elevated troponins. Heart 2006;92:987-93.
5. Kociol RD, Pang PS, Gheorghiade M, Fonarow GC, O'Connor CM, Felker GM. Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. J Am Coll Cardiol 2010;56:1071-8.
6. Missov E, Mair J. A novel biochemical approach to congestive heart failure: cardiac troponin T. Am Heart J 1999;138:95-9.
7. Nussinovitch U, Shoenfeld Y. Anti-troponin autoantibodies and the cardiovascular system. Heart 2010;96:1518-24.
8. Matsuoka S, Kurahashi Y, Miki Y, Miyao M, Yamazaki Y, Nishiuchi T et al. Plasma atrial natriuretic peptide in patients with congenital heart diseases. Pediatrics 1988;82:639-43.
9. Nir A, Lindinger A, Rauh M, Bar-Oz B, Laer S, Schwachtgen L et al. NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies. Pediatr Cardiol 2009;30:3-8.
10. Eerola A, Jokinen E, Sairanen H, Pihkala J. During treatment protocol for univentricular heart serum levels of natriuretic peptides decrease. Eur J Cardiothorac Surg 2010;38:735-40.
11. Eriksson S, Ilva T, Becker C, Lund J, Porela P, Pulkki K et al. Comparison of cardiac troponin I immunoassays variably affected by circulating autoanti-bodies. Clin Chem 2005;51:848-55.
12. Eriksson S, Halenius H, Pulkki K, Hellman J, Pettersson K. Negative interference in cardiac troponin I immunoassays by circulating troponin autoanti-bodies. Clin Chem 2005;51:839-47.
13. Lopez L, Colan SD, Frommelt PC, Ensing GJ, Kendall K, Younoszai AK et al. Recommendations for quantification methods during the performance of a pediatric echocardiogram: a report from the pediatric measurements writing group of the American society of echocardiography pediatric and congenital heart disease council. J Am Soc Echocardiogr 2010;23:465-95; quiz 576-7.
14. Gewillig M. The Fontan circulation. Heart 2005;91:839-46.
15. Adamcova M. Troponins in children and neonates. Acta Paediatr 2003;92: 1373-5.
16. Masson S, Latini R, Anand IS. An update on cardiac troponins as circulating biomarkers in heart failure. Current Heart Failure Reports 2010;7:15-21.
17. Ohye RG, Devaney EJ, Hirsch JC, Bove EL. The modified Blalock-Taussig shunt versus the right ventricle-to-pulmonary artery conduit for the Norwood procedure. Pediatr Cardiol 2007;28:122-5.
18. Adamczyk M, Brashear RJ, Mattingly PG. Prevalence of autoantibodies to cardiac troponin T in healthy blood donors. Clin Chem 2009;55:1592-3.
19. Shah A, Feraco AM, Harmon C, Tacy T, Fineman JR, Bernstein HS. Usefulness of various plasma biomarkers for diagnosis of heart failure in children with single ventricle physiology. Am J Cardiol 2009;104: 1280-4.
20. Eindhoven JA, van den Bosch AE, Jansen PR, Boersma E, Roos-Hesselink JW. The usefulness of brain natriuretic peptide in complex congenital heart disease: a systematic review. J Am Coll Cardiol 2012;60:2140-9.
21. Inuzuka R, Tatebe S, Wakiguchi S, Nakajima H, Ohtsu H, Dimopoulos K et al. B-type natriuretic peptide at the early stage of univentricular circulation reflects inadequate adaptation to volume overload. Int J Cardiol 2012; 159:88-93.
22. Hopkins WE, Chen Z, Fukagawa NK, Hall C, Knot HJ, LeWinter MM. Increased atrial and brain natriuretic peptides in adults with cyanotic congenital heart disease: enhanced understanding of the relationship between hypoxia and natriuretic peptide secretion. Circulation 2004;109: 2872-7.